US FDA Feedback on Type C Meeting for ATL1102 in the US
- Clarity on path forward for a Phase IIb/III including the potential exploration of higher doses
- Company to submit Fast Track Designation Request based on FDA feedback
http://www.antisense.com.au/wp-content/uploads/2021/06/ASX-21_-1-June_ATL1102-FDA-Type-C-meeting.pdf
Where others have failed will Atl1102 succeed ?, page-200
Add PER (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
13.5¢ |
Change
0.000(0.00%) |
Mkt cap ! $121.7M | |||
| Open | High | Low | Value | Volume |
| 0.0¢ | 0.0¢ | 0.0¢ | $0 | 0 |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 35714 | 14.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 9.8¢ | 37037 | 1 |
View Market Depth
| Last trade - 16.12pm 17/10/2024 (20 minute delay) ? |
| PER (ASX) Chart |
Day chart unavailable